Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications - PubMed (original) (raw)
Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications
L Benvegnù et al. Gut. 2004 May.
Abstract
Background and aims: The natural history of initially compensated cirrhosis due to hepatitis B (HBV) or hepatitis C (HCV) virus is only partially defined. We have investigated morbidity and mortality rates and the hierarchy of complications in compensated viral cirrhosis over a long follow up period.
Patients and methods: A cohort of Italian patients with initially compensated cirrhosis of viral aetiology were followed up at six monthly intervals with laboratory tests to identify major complications (ascites, gastrointestinal bleeding, portal-systemic encephalopathy, hepatocellular carcinoma) and to assess the progression of Child's stage and mortality rate due to liver related causes.
Results: Between 1986 and 1996, 312 patients (43 HBV positive, 254 HCV positive, and 15 HBV and HCV coinfected) were included. During a median follow up of 93 (range 14-194) months, 102 (32.6%) patients developed at least one complication (HCV positive 31.1%; HBV positive 34.8%; HBV and HCV coinfected 53.3%). Overall, the most frequent complication was hepatocellular carcinoma which occurred in 65 (20.8%) cases, followed by ascites (61 cases, 19.5%), gastrointestinal bleeding (14 cases, 4.5%), and portal-systemic encephalopathy (six cases, 1.9%). Progression of Child's stage was observed in 62 patients (19.8%). Death from liver disease occurred in 58 (18.6%) cases and in 70.7% this was due to hepatocellular carcinoma. Hepatocellular carcinoma was the first complication to develop in 59 cases and represented the most frequent first complication in both HCV and HBV/ HCV related cirrhosis.
Conclusions: These results indicate significant morbidity and mortality during the first decade after diagnosis of compensated cirrhosis due to HBV and/or HCV, and identify hepatocellular carcinoma as the most frequent and life threatening complication, particularly in HCV positive cases.
Figures
Figure 1
Cumulative probability of hepatocellular carcinoma (HCC), ascites, variceal bleeding, and portal-systemic encephalopathy during follow up in 312 patients with initially compensated cirrhosis of viral aetiology (Kaplan-Meier method).
Figure 2
Incidence of hepatocellular carcinoma (HCC) and liver related mortality rate during follow up in the whole population (Kaplan-Meier method).
Figure 3
Cumulative incidence of ascites appearance in relation to development of hepatocellular carcinoma (HCC) during follow up (Kaplan-Meier method and log rank test).
Figure 4
Cumulative probability of hepatocellular carcinoma (HCC) (A), ascites (B), variceal bleeding (C), and portal-systemic encephalopathy (D) during follow up in the different aetiological subgroups (Kaplan-Meier method). HCV, hepatitis C virus; HBsAg, hepatitis B surface antigen.
Similar articles
- [Viral liver cirrhosis: natural course, pathogenesis and clinical implications of the complications].
Gentilini P, Laffi G, La Villa G, Casini-Raggi V, Romanelli RG, Buzzelli G, Mazzanti R, Marra F, Pinzani M, Zignego AL. Gentilini P, et al. Ann Ital Med Int. 1996 Oct;11 Suppl 2:23S-29S. Ann Ital Med Int. 1996. PMID: 9004817 Italian. - Extrahepatic cancers are the leading cause of death in patients achieving hepatitis B virus control or hepatitis C virus eradication.
Allaire M, Nahon P, Layese R, Bourcier V, Cagnot C, Marcellin P, Guyader D, Pol S, Larrey D, De Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Riachi G, Calès P, Péron JM, Alric L, Bourlière M, Mathurin P, Blanc JF, Abergel A, Serfaty L, Mallat A, Grangé JD, Attali P, Bacq Y, Wartelle C, Dao T, Thabut D, Pilette C, Silvain C, Christidis C, Nguyen-Khac E, Bernard-Chabert B, Zucman D, DI Martino V, Sutton A, Letouzé E, Audureau E, Roudot-Thoraval F; ANRS CO12 CirVir Group. Allaire M, et al. Hepatology. 2018 Oct;68(4):1245-1259. doi: 10.1002/hep.30034. Epub 2018 Jul 10. Hepatology. 2018. PMID: 29663511 - Validation of Baveno VI Criteria for Screening and Surveillance of Esophageal Varices in Patients With Compensated Cirrhosis and a Sustained Response to Antiviral Therapy.
Thabut D, Bureau C, Layese R, Bourcier V, Hammouche M, Cagnot C, Marcellin P, Guyader D, Pol S, Larrey D, De Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Goria O, Calès P, Péron JM, Alric L, Bourlière M, Mathurin P, Blanc JF, Abergel A, Serfaty L, Mallat A, Grangé JD, Attali P, Bacq Y, Wartelle-Bladou C, Dao T, Pilette C, Silvain C, Christidis C, Capron D, Bernard-Chabert B, Hillaire S, Di Martino V, Sutton A, Audureau E, Roudot-Thoraval F, Nahon P; ANRS CO12 CirVir group. Thabut D, et al. Gastroenterology. 2019 Mar;156(4):997-1009.e5. doi: 10.1053/j.gastro.2018.11.053. Epub 2019 Feb 13. Gastroenterology. 2019. PMID: 30768988 - Natural history of chronic hepatitis B and C.
Imperial JC. Imperial JC. J Gastroenterol Hepatol. 1999 May;14 Suppl:S1-5. doi: 10.1046/j.1440-1746.1999.01903.x. J Gastroenterol Hepatol. 1999. PMID: 10382630 Review. - A review of the treatment of chronic hepatitis C virus infection in cirrhosis.
Vezali E, Aghemo A, Colombo M. Vezali E, et al. Clin Ther. 2010 Dec;32(13):2117-38. doi: 10.1016/S0149-2918(11)00022-1. Clin Ther. 2010. PMID: 21316532 Review.
Cited by
- Management of renal failure and ascites in patients with cirrhosis.
Madan K, Mehta A. Madan K, et al. Int J Hepatol. 2011;2011:790232. doi: 10.4061/2011/790232. Epub 2011 Sep 27. Int J Hepatol. 2011. PMID: 21994871 Free PMC article. - Short-Term Western Diet Aggravates Non-Alcoholic Fatty Liver Disease (NAFLD) With Portal Hypertension in TGR(mREN2)27 Rats.
Cremonese C, Schierwagen R, Uschner FE, Torres S, Tyc O, Ortiz C, Schulz M, Queck A, Kristiansen G, Bader M, Sauerbruch T, Weiskirchen R, Walther T, Trebicka J, Klein S. Cremonese C, et al. Int J Mol Sci. 2020 May 7;21(9):3308. doi: 10.3390/ijms21093308. Int J Mol Sci. 2020. PMID: 32392802 Free PMC article. - The Epidemiology of Hepatocellular Carcinoma in the USA.
Kim HS, El-Serag HB. Kim HS, et al. Curr Gastroenterol Rep. 2019 Apr 11;21(4):17. doi: 10.1007/s11894-019-0681-x. Curr Gastroenterol Rep. 2019. PMID: 30976932 Review. - Intent-to-treat analysis of liver transplant for hepatocellular carcinoma in the MELD era: impact of hepatitis C and advanced status.
Hu Z, Li Z, Xiang J, Zhou J, Yan S, Wu J, Zhou L, Zheng S. Hu Z, et al. Dig Dis Sci. 2014 Dec;59(12):3062-72. doi: 10.1007/s10620-014-3266-4. Epub 2014 Jul 10. Dig Dis Sci. 2014. PMID: 25008426 - Step by Step: Managing the Complications of Cirrhosis.
Perez IC, Bolte FJ, Bigelow W, Dickson Z, Shah NL. Perez IC, et al. Hepat Med. 2021 May 25;13:45-57. doi: 10.2147/HMER.S278032. eCollection 2021. Hepat Med. 2021. PMID: 34079394 Free PMC article. Review.
References
- Margolis HS, Alter MJ, Hadler SC. Hepatitis B: evolving epidemiology and implication for controls. Semin Liver Dis 1991;11:84–92. - PubMed
- Lok AS, Heathcote EJ, Hoofnagle YH. Managment of hepatitis B: 2000—Summary of a Workshop. Gastroenterology 2001;120:1828–53. - PubMed
- Global surveillance, control of hepatitis C. Report of a WHO consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 1999;6:35–47. - PubMed
- National Institute of Health Consensus Development Conference Panel statement: management of hepatitis C. Hepatology 1997;26(suppl 1):2S–10. - PubMed
- EASL International Consensus Conference on Hepatitis C: Paris, 26–28 February 1999, consensus statement. J Hepatol 1999;30:956–61. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical